Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Cannabis for Pain Relief: An Area Ripe for Research

Vanessa Caceres  |  September 28, 2023

Medical cannabis may benefit patients experiencing pain, and rheumatologists should be able to discuss its potential risks and benefits with their patients. Here are insights from Dr. Mary Ann Fitzcharles on current research, patient use and more.

Glucocorticoid Use at Any Dose Increases Fracture Risk

Arthritis & Rheumatology  |  September 26, 2023

The accepted wisdom is that the negative effects of glucocorticoids on bone depend on the dose and treatment duration. Adami et al. conducted this study to determine, in a real-life setting, the risk of fragility fracture associated with the dose of glucocorticoids in patients with inflammatory rheumatic musculoskeletal diseases.

Findings from a Clinical Trial of Dazodalibep for Sjögren’s Disease

Michele B. Kaufman, PharmD, BCGP  |  September 26, 2023

St.Clair et al. found that patients with Sjögren’s disease treated with dazodalibep experienced greater improvement in key symptoms of dryness, fatigue and pain than patients who received placebo.

The ACR Launches Rheumatoid Arthritis Measures Toolkit

Allison Plitman, MPA  |  September 25, 2023

The new resource offers standardized outcome measures for providers who treat patients with RA, as well as training materials for medical staff to guide accurate and efficient data collection. It also includes video tutorials and sample workflows for different EHR systems.

Updates from the ACR Insurance Subcommittee Chair

Rebecca Shepherd, MD, MBA, FACR, FACP  |  September 25, 2023

The Insurance Subcommittee is working to address coverage and reimbursement challenges facing rheumatology practices. Recent activities include efforts to avoid increased administrative burden associated with specialty medications, support payer coverage of musculoskeletal ultrasounds and protect patient access to biologics.

Break Barriers: Engaging Diverse Participants in Clinical Trials for Patients with Lupus

Jason Liebowitz, MD, FACR  |  September 14, 2023

Misinformation, fear and not having a trusted partner in the medical sector are just a few of the barriers that prevent patients of color from being adequately represented in research and clinical trials for lupus. Experts and patient advocates addressed how to remove these barriers and more during the 2023 ACR Diversification of Clinical Trials Summit.

Investigational Nanobody Compound Shows Promise for RA Treatment

Michele B. Kaufman, PharmD, BCGP  |  September 14, 2023

In Japan, ozoralizumab will soon be available as a 30 mg subcutaneous auto-injection to treat patients with rheumatoid arthritis.

Late Summer 2023’s Awards, Appointments & Announcements in Rheumatology

Gretchen Henkel  |  September 11, 2023

PANLAR Names Eric L. Matteson, MD, a 2023 Master Throughout his career at the Mayo Clinic, Rochester, Minn., Eric L. Matteson, MD, currently professor of rheumatology, emeritus, actively engaged with his rheumatology colleagues in Latin America. He participated in conferences, worked on South American publications and brought rheumatology fellows to the Mayo Clinic for training….

Rheum After 5: Dr. Christopher Morris, Jeopardy! Contestant

Carol Patton  |  September 11, 2023

The clock was ticking. Christopher Morris, MD, then an intern and resident in internal medicine at the University of Tennessee (UT) Medical Center, Knoxville, had just 30 seconds to think of the correct response. He already had the answer. His challenge was coming up with the question. Final Jeopardy In 1988, Dr. Morris, now a…

The Vital Role of the Physician Assistant

Leslie Mertz, PhD  |  September 11, 2023

A team approach is necessary to provide comprehensive care in today’s complex healthcare settings. And nowhere is the need for a cadre of medical professionals more evident than within the practice of rheumatology, where complicated diagnoses and tailored treatments are the rule rather than the exception. Among the highly trained members of these healthcare teams…

  • « Previous Page
  • 1
  • …
  • 59
  • 60
  • 61
  • 62
  • 63
  • …
  • 814
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences